BioCentury
ARTICLE | Company News

Cerus completes PMA for Intercept Blood System for plasma

December 5, 2013 1:55 AM UTC

Cerus Corp. (NASDAQ:CERS) submitted the final module of a PMA for the company's Intercept Blood System for plasma. In March, the company plans to submit the final module for a PMA for the system for platelets. The Intercept Blood System, which uses light-activated molecules to crosslink DNA and RNA to prevent pathogen replication, already has CE Mark approval for platelets and plasma, and Cerus markets the system in Europe to inactivate blood-borne pathogens in donated blood components intended for transfusion. ...